ABP 938 — Competitive Intelligence Brief

ABP 938 (ABP 938) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RANKL inhibitor. Area: Bone metabolism / Osteoporosis.

phase 3 RANKL inhibitor RANKL Bone metabolism / Osteoporosis Small molecule

Target snapshot

ABP 938 (ABP 938) — Amgen. ABP 938 is a RANKL inhibitor that blocks osteoclast activation and bone resorption.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ABP 938 TARGET	ABP 938	Amgen	phase 3	RANKL inhibitor	RANKL
Romosozumab followed by Denosumab	Romosozumab followed by Denosumab	National Taiwan University Hospital	marketed	Sclerostin inhibitor followed by RANKL inhibitor	Sclerostin (romosozumab); RANKL (Denosumab)
Denosumab De-escalation	Denosumab De-escalation	National Taiwan University Hospital	marketed	RANKL inhibitor monoclonal antibody de-escalation strategy	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
BONCRESA	DENOSUMAB-MOBZ	AMNEAL PHARMS LLC	marketed	RANK Ligand Inhibitor [EPC]	RANKL
Placebo to Denosumab	Placebo to Denosumab	Amgen	marketed	RANKL inhibitor (monoclonal antibody)	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
Xgeva®	Xgeva®	Jiangsu Hansoh Pharmaceutical Co., Ltd.	marketed	RANKL inhibitor (monoclonal antibody)	RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand)
Romosozumab and Denosumab Cycle Therapy	Romosozumab and Denosumab Cycle Therapy	National Taiwan University Hospital	marketed	Bone-forming agent and antiresorptive agent combination therapy	Sclerostin (romosozumab); RANKL (denosumab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RANKL inhibitor class)

1. Amgen · 4 drugs in this class